View Older Stories View More Recent Stories

Jun 3, 2023 01:30PM Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
Jun 1, 2023 08:34AM Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
May 26, 2023 01:00AM CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
May 25, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
May 17, 2023 08:30AM Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
May 16, 2023 04:02PM Gilead Sciences (GILD) Appoints Cindy Perettie as EVP of Kite
May 16, 2023 04:01PM Gilead Appoints Cindy Perettie Executive Vice President of Kite
May 15, 2023 08:30AM Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
May 9, 2023 08:31AM Gilead Sciences (GILD) Announces Acquisition of XinThera
May 9, 2023 08:30AM Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
May 4, 2023 07:02AM Gilead Sciences (GILD) Reports Positive CHMP Opinion for Hepcludex
May 4, 2023 07:00AM CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
May 1, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 16, 2023 04:00AM Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
Apr 13, 2023 04:05PM Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
Mar 29, 2023 10:35AM Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
Mar 22, 2023 12:00PM Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
Mar 21, 2023 09:38AM Gilead Sciences (GILD) Announces Kite's Yescarta CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in OS for Initial Treatment of R/R Large B-cell Lymphoma
Mar 21, 2023 09:37AM Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Mar 20, 2023 08:30AM Gilead Sciences (GILD) Exercises Option to License Nurix’s (NRIX) NX-0479
Mar 20, 2023 08:30AM Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
Mar 20, 2023 08:30AM Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
Feb 22, 2023 11:21AM Gilead Sciences (GILD) Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the
Feb 22, 2023 11:21AM Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
Feb 22, 2023 09:03AM Gilead Sciences' (GILD) Kite Completes Acquisition of Tmunity
Feb 22, 2023 09:00AM Kite Completes Acquisition of Tmunity
Feb 21, 2023 05:30PM Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
Feb 21, 2023 03:01PM Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
Feb 17, 2023 09:00AM Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
Feb 14, 2023 08:45AM Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
Feb 9, 2023 07:34AM Gilead Sciences' (GILD) Kite Announces Tecartus CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in R/R B-Cell ALL
Feb 9, 2023 07:15AM Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Feb 3, 2023 10:29AM Gilead Sciences (GILD) Announces FDA Approval of Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
Feb 3, 2023 10:29AM U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Feb 1, 2023 08:35AM Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
Jan 30, 2023 09:00AM Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Jan 27, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Jan 19, 2023 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
Jan 5, 2023 01:50PM Gilead Sciences Again Named to Dow Jones Sustainability World Index
Jan 3, 2023 08:31AM Gilead Sciences (GILD) Announces Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
Jan 3, 2023 08:31AM Gilead Sciences (GILD) and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Jan 3, 2023 08:30AM Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Jan 3, 2023 08:30AM European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
Dec 27, 2022 04:30PM Gilead Sciences (GILD) to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics (JNCE)
Dec 27, 2022 04:30PM Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Dec 27, 2022 04:30PM Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
Dec 23, 2022 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 22, 2022 10:28AM Gilead Sciences (GILD) Sunlenca approved by FDA for HIV-1
Dec 22, 2022 10:27AM Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Dec 20, 2022 08:00AM Gilead's (GILD) Kite Acquires Tmunity Therapeutics
View More Recent Stories View Older Stories